ArticleFrontiers in immunology2026
Resveratrol alleviates functional dyspepsia-like pathology by modulating chemokine- and cytokine-related immune-epithelial signaling in the duodenal mucosa.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Resveratrol is a dietary polyphenol found in grapes, peanuts, and berries, with reported anti-inflammatory, immunomodulatory, barrier-protective, and microbiota-regulating properties. Functional dyspepsia (FD) is associated with duodenal immune dysregulation, epithelial barrier impairment, and microbial imbalance, suggesting an active mucosal microenvironment. This study therefore examined whether resveratrol could alleviate FD-like pathological changes. We also examined its links with epithelial homeostasis, gut microbiota, and chemokine- or cytokine-related ligand-receptor signaling. Methods: An FD-like mouse model was established and treated with resveratrol. Gastric emptying was assessed, and duodenal histopathology was examined by hematoxylin-eosin staining, including epithelial injury, goblet cell alterations, crypt disorganization, and inflammatory cell infiltration. Toluidine blue staining assessed mast cell accumulation. RNA sequencing, GO/KEGG enrichment, and protein-protein interaction analyses characterized immune-related pathways, hub genes, and potential signaling networks. qPCR validated genes related to mucosal metabolism and epithelial function, chemokine- and cytokine-related ligand-receptor signaling genes, mast cell markers, and epithelial barrier genes. 16S rRNA sequencing assessed gut microbial changes. Results: FD-like mice showed delayed gastric emptying, duodenal mucosal injury, inflammatory cell infiltration, goblet cell alterations, crypt disorganization, and mast cell accumulation, indicating low-grade mucosal immune activation and epithelial barrier disturbance. Resveratrol improved gastric emptying, alleviated duodenal injury, and reduced mast cell infiltration. Transcriptomic analysis showed broad changes in immune-related programs, particularly those associated with antigen presentation, adaptive immune responses, pro-inflammatory signaling, chemokine and cytokine activity, and mucosal immune regulation. PPI and qPCR analyses further supported the regulation of mucosal homeostasis, candidate Conclusion: Resveratrol attenuates FD-like gastric dysmotility and duodenal inflammatory injury, potentially by reducing mast cell-associated mucosal immune activation, modulating chemokine- and cytokine-related immune-epithelial signaling, supporting epithelial barrier homeostasis, and reshaping gut microbiota.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.